Comparison of Octreotide Scintigraphy and Conventional Imaging in Medullary Thyroid Carcinoma

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 912-916

  Baudin, E ^a   Lumbroso, J ^a   Schlumberger, M ^a   Leclere, J ^a   Giammarile, F ^a   Gardet, P ^a   Roche, A ^a   Travagli, J P ^a   Parmentier, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Indium 111 octreotide; Medullary thyroid carcinoma; Scintigraphy

Indexed keywords

DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; OCTREOTIDE; PENTETIC ACID; PENTETREOTIDE; SDZ 215 811; SDZ 215-811; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; FEMALE; HUMAN; LIVER TUMOR; MALE; MEDULLARY CARCINOMA; METASTASIS; MIDDLE AGED; PROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID TUMOR;

ADULT; AGED; CARCINOMA, MEDULLARY; FEMALE; HUMANS; INDIUM RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; PENTETIC ACID; PROSPECTIVE STUDIES; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030162739     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wahl RA, Roher AD. Surgery of C cell carcinoma of the thyroid. Prog Surg 1988;19:100-112.
2. Parmentier C, Gardet P, De Vathaire F, et al. Prognostic factors in medullary thyroid carcinoma (MTC): a study based on 207 patients treated al the Institut Gustav Roussy. In: Calmettes C, Guliana JM, eds. Medullary thyroid carcinoma. John Libbey, Eurotext Ltd; 1991:193-198.
3. Abdelmoumene N, Schlumberger M, Gardet P, et al. Selective venous sampling catheterization for localization of persisting medullary carcinoma. Br J Cancer 1994;69:1141-1144.
4. Baulieu JL, Guilloteau D, Delisle MJ, et al. Radioiodinated metaiodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer 1987;60:2189-2194.
5. Arnstein NB, Juni JE, Sisson JC, et al. Recurrent thyroid carcinoma of the thyroid demonstrated by thallium-201 scintigraphy. J Nucl Med 1986;27:1564-1568.
6. Miyauchi A, Endo K, Ohta H, et al. Technetium-99m-(V)-dimercaptosuccinic acid scintigraphy for medullary thyroid carcinoma. World J Surg 1986;10:640-645.
7. Manil L, Boudet F, Motte P, et al. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma and small-lung cancer. Cancer Res 1989;49:5480-5485.
8. Berche C, Mach JP, Lumbroso JD, et al. Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancer: first clinical results using radiolabeled monoclonal antibodies against carcinoembryonic antigen. Br Med J 1982;285:1447-1451.
9. Lamberts SWJ, Krenning E, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev 1991;12:450-482.
10. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413-1417.
11. Dörr U, Sautter-Bihl ML, Bhil H. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol 1994;421(suppl 13):42-45.
12. Krausz Y, Ish-Shalom S, Dejong RBJ, et al. Somatostatin receptor imaging of medullary thyroid carcinoma. Clin Nucl Med 1994;19:416-421.
13. Motte P, Vauzelle P, Gardet P, et al. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal antipeptide antibodies. Clin Chim Acta 1988;174:35-54.
14. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
15. Reubi JC, Kvols L, Krenning E, et al. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol 1993;30:463-468.
16. Reubi JC, Chayvialle A, Franc B, et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64:567-573.
17. Modigliani E, Cohen R, Joannidis S, et al. Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 1992;36:183-186.